15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 22 firms covering Medtronic PLC, 16 rate it Buy or better, 6 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $83.00 to $120.00, a moderate spread. The average target of $104.86 sits 14% above the current $91.96. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 14 to 16 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.42 next quarter toward $6.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS22 ratings
Moderate Buy
Strong Buy00%
Buy1673%
Hold627%
Sell00%
Strong Sell00%
Based on 22 analysts giving stock ratings to Medtronic PLC.
As of Sep, 16 of 22 firms rate MDT a Buy (6 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MDT EPS & revenue forecast
EPS · NEXT QUARTER
$1.42
Range $1.38 – $1.48 · 22 analysts · +5% YoY
Next period, 22 analysts expect Medtronic PLC to earn $1.42 a share (range $1.38 – $1.48), versus $1.36 a year earlier. Full-year consensus is $5.97, growing to $6.40 the year after.
REVENUE · NEXT QUARTER
$9.5B
Range $9.5B – $9.7B · 22 analysts · +6% YoY
Revenue is expected to reach $9.5B (range $9.5B – $9.7B), +5.7% year-over-year. Full-year consensus is $39.0B, rising to $40.4B next year.
Top analysts covering Medtronic PLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MDT.
#1
Anthony Petrone
Mizuho · Rank #86
Buy
$115.00+25.1% to target
Overall win rate
46%
+ Follow
#2
JB
Jayson Bedford
Raymond James · Rank #196
Hold
No targeton MDT
Overall win rate
42%
+ Follow
#3
Mike Matson
Needham · Rank #210
Buy
$114.00+24.0% to target
Overall win rate
34%
+ Follow
#4
Matt O'Brien
Piper Sandler · Rank #424
Hold
$91.00-1.0% to target
Overall win rate
25%
+ Follow
#5
LB
Larry Biegelsen
Wells Fargo
Buy
$104.00+13.1% to target
Coverage
—
+ Follow
MDT stock forecast FAQ
What is MDT's average 12-month price target?+
The 21 analysts with a live target average $104.86 for Medtronic PLC over the next 12 months, ranging from a $120.00 high to a $83.00 low.
Is MDT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 22 analyst ratings, 16 are Buy or Strong Buy, 6 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MDT?+
The Street-high target is $120.00 (Barclays), and the Street-low is $83.00 (Goldman Sachs). The average of all 21 active targets is $104.86.
How many Wall Street analysts cover MDT?+
22 analysts have an active rating on Medtronic PLC, and 21 firms carry a live 12-month price target.
Who is the most accurate analyst covering MDT?+
Among analysts who currently cover MDT, Anthony Petrone of Mizuho has the strongest overall Quantellect track record (Rank #86). Their current call is Buy with a $115.00 target.
What is Medtronic PLC's projected EPS for next quarter?+
The consensus estimate is $1.42 per share (range $1.38 – $1.48) across 22 analysts. Full-year EPS is projected at $5.97, rising to $6.40 the following year.
How much revenue is Medtronic PLC expected to report next quarter?+
Consensus revenue is $9.5B (range $9.5B – $9.7B). Full-year revenue is projected at $39.0B, growing to $40.4B next year.
Have analysts been upgrading or downgrading MDT lately?+
As of Sep, 16 of 22 firms rate MDT a Buy (6 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MDT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
RBC Capital
